Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT02993029
Recruiting Not applicable

99Tc-MDP Treatment for Knee Osteoarthritis

NCT02993029 · tracked via the Priya Life Science China tracker
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Not applicable
Started
2017-09-01
Last updated
2026-04-28

Condition(s) studied

Treatment Outcome

Investigational drug(s) / intervention(s)

99Tc-MDPCelecoxib →

99Tc-MDP: 99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.

Celecoxib: Celecoxib capsule 200mg qd by mouth.

Study summary

Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.

Eligibility

Sex
ALL
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Participants with painful osteoarthritis; 2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan; 3. Participants voluntarily participate in the trial, and signed the informed consent. Exclusion Criteria: 1. Knee joint replacement; 2. Inflammatory arthritis or joint infection of knee; 3. Nervous joint disease; 4. Fracture of joint; 5. Gout arthritis of the knee; 6. Traumatic arthritis.

Primary outcome measure(s)

  • pain, stiffness and joint function of knee — baseline, and 6, 12 months after treatment.
    change of the pain, stiffness and joint function of knee (mean and standard deviation) by Western Ontario and McMaster Universities (WOMAC)Osteoarthritis Index

Trial sites (1)

FacilityCityRegionStatus
Department of Nuclear Medicine, Tenth People's Hospital of Tongji University Shanghai Shanghai Municipality Recruiting

More Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials in China

AI-Based Ultrasound Prediction of Pregnancy Outcomes in Placental-Related Fetal Growth Restriction (MVM-FGR): A Prospective Cohort Study Recruiting
Research on Body Voice AI Recognition System for Children's Health Management Recruiting
A Clinical Study on the Efficacy of Cognitive Distraction Focus Relaxation Therapy Based on MR Recruiting
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations Recruiting
PEELED INTERNAL LIMITING MEMBRANE REPOSITION Recruiting

Other trials for the same condition

A Real World Study of Sacituzumab Govitecan Recruiting
Urinary Continence of Female POPRC and OIN Starting soon
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02993029 on ClinicalTrials.gov ↗ ← All trials in China